Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isoken Odia

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Contemporary Clinical Trials Communications|May 9, 2018
Characterizing permuted block randomization as a big stick procedureVance W Berger, Isoken Odia
JAMA Ophthalmology|June 28, 2019
Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical TrialNeil M Bressler, Isoken Odia, Maureen Maguire, et al.
Retina (Philadelphia, Pa.)|September 21, 2018
CHANGES IN DIABETIC RETINOPATHY SEVERITY WHEN TREATING DIABETIC MACULAR EDEMA WITH RANIBIZUMAB: DRCR.net Protocol I 5-Year ReportSusan B Bressler, Isoken Odia, Adam R Glassman, et al.
JAMA Ophthalmology|January 25, 2019
Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti-Vascular Endothelial Growth Factor Therapy: An Exploratory Analysis of the Protocol T Randomized Clinical TrialSusan B Bressler, Isoken Odia, Maureen G Maguire, et al.
Retina (Philadelphia, Pa.)|November 15, 2017
PANRETINAL PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Comparison of Peripapillary Retinal Nerve Fiber Layer Thickness in a Randomized Clinical TrialLee M Jampol, Isoken Odia, Adam R Glassman, et al.
JAMA Ophthalmology|October 23, 2018
Comparison of Early Treatment Diabetic Retinopathy Study Standard 7-Field Imaging With Ultrawide-Field Imaging for Determining Severity of Diabetic RetinopathyLloyd Paul Aiello, Isoken Odia, Adam R Glassman, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Contemporary Clinical Trials Communications|May 9, 2018
Characterizing permuted block randomization as a big stick procedureVance W Berger, Isoken Odia
JAMA Ophthalmology|June 28, 2019
Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical TrialNeil M Bressler, Isoken Odia, Maureen Maguire, et al.
Retina (Philadelphia, Pa.)|September 21, 2018
CHANGES IN DIABETIC RETINOPATHY SEVERITY WHEN TREATING DIABETIC MACULAR EDEMA WITH RANIBIZUMAB: DRCR.net Protocol I 5-Year ReportSusan B Bressler, Isoken Odia, Adam R Glassman, et al.
JAMA Ophthalmology|January 25, 2019
Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti-Vascular Endothelial Growth Factor Therapy: An Exploratory Analysis of the Protocol T Randomized Clinical TrialSusan B Bressler, Isoken Odia, Maureen G Maguire, et al.
Retina (Philadelphia, Pa.)|November 15, 2017
PANRETINAL PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Comparison of Peripapillary Retinal Nerve Fiber Layer Thickness in a Randomized Clinical TrialLee M Jampol, Isoken Odia, Adam R Glassman, et al.
JAMA Ophthalmology|October 23, 2018
Comparison of Early Treatment Diabetic Retinopathy Study Standard 7-Field Imaging With Ultrawide-Field Imaging for Determining Severity of Diabetic RetinopathyLloyd Paul Aiello, Isoken Odia, Adam R Glassman, et al.
Pageof 1